Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2003-05-14

Last Posted Date: 2012-06-06

Lead Sponsor: Northwestern University

Registration Number: NCT00004916

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx

Phase 2

Conditions: Head and Neck Cancer

First Posted Date: 2003-05-08

Last Posted Date: 2014-01-06

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00004094

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
Monroe Medical Associates, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 1 locations

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IIIA Non-small Cell Lung Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: motexafin gadolinium
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-05-07

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00005065

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Phase 2

Completed

Conditions: Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Ovarian Undifferentiated Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Brenner Tumor
Ovarian Clear Cell Cystadenocarcinoma
Fallopian Tube Cancer
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: erlotinib

First Posted Date: 2003-05-07

Last Posted Date: 2015-12-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT00059787

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2003-05-07

Last Posted Date: 2015-11-17

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 35

Registration Number: NCT00016315

Locations: 🇺🇸
CCOP - Bay Area Tumor Institute, Oakland, California, United States
🇺🇸
Wendt Regional Cancer Center of Finley Hospital, Dubuque, Iowa, United States
🇺🇸
Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States

and more 16 locations

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-05-07

Last Posted Date: 2022-02-03

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 19

Registration Number: NCT00043108

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer
Oral Complications

Interventions: Drug: amifostine trihydrate
Drug: paclitaxel
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-04-23

Last Posted Date: 2012-12-06

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 37

Registration Number: NCT00003193

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer

First Posted Date: 2003-04-18

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00003064

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Paclitaxel in Treating Patients With Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2003-04-17

Last Posted Date: 2012-07-02

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 25

Registration Number: NCT00002972

Locations: 🇮🇹
Azienda Ospedale S. Luigi - Universita Di Torino, Orbassano, (Torino), Italy
🇩🇪
Universitaetsklinik und Strahlenklinik - Essen, Essen, Germany
🇧🇪
Centre Hospitalier Regional de la Citadelle, Liege (Luik), Belgium

and more 2 locations

Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: bortezomib
Drug: paclitaxel
Other: laboratory biomarker analysis

First Posted Date: 2003-04-09

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00030368

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy